Skip to content

US · PBLS · BIOTECHNOLOGY

Parabilis Medicines, Inc. (PBLS) intrinsic value and stock valuation

$41.73as of 2026-09-18 · Mkt cap 4.3B

Data updated · price as of 2026-09-18

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Parabilis Medicines, Inc. DCF and intrinsic value

InvestorsCraft values PBLS with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from PBLS’s statements →

Parabilis Medicines, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA, US parabilismed.com

How the business is doing

Fiscal 2025–2024, USD

Revenue
$0.00
20252024
Net income
-$-117.91T
20252024
Free cash flow
-$-104.49T
20252024
Total equity
$56.4T
20252024

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2024, USD
FYFY
Revenue$0.00$0.00
Operating income-$-152.08T-$-126.13T
Net income-$-145.89T-$-117.91T
EPSd-$-72.11M-$-60.96M
Operating cash flow-$-123.71T-$-103.61T
Capital expenditure-$-306B-$-879B
Free cash flow-$-124.02T-$-104.49T
Total assets$80.8T$149.3T
Total debt$58.7T$66.2T
Net debt$31T$18.9T
Total equity-$-16.52T$56.4T
Cash and short-term investments$27.7T$88T
Income statement
FYFY
Revenue$0.00$0.00
Cost of revenue$0.00$0.00
Gross profit$0.00$0.00
Research and development expenses$125.6T$100.8T
Selling, general and administrative expenses$26.5T$25.3T
Other expenses$0.00$0.00
Operating expenses$152.1T$126.1T
Cost and expenses$152.1T$126.1T
Interest income$3.39T$6.41T
Interest expense$1.52T$1.49T
Depreciation and amortization$2.5T$2.1T
Ebitda-$-141.87T-$-114.33T
Operating income-$-152.08T-$-126.13T
Total other income/expenses, net$6.19T$8.21T
Income before tax-$-145.89T-$-117.91T
Income tax expense$0.00$0.00
Net income-$-145.89T-$-117.91T
Weighted average shares outstanding$2.02T$1.93T
Weighted average diluted shares outstanding$2.02T$1.93T
Balance sheet
FYFY
Cash and short-term investments$27.7T$88T
Net receivables$0.00$360B
Inventory$0.00$0.00
Total current assets$29.4T$92.2T
Property, plant and equipment, net$46.1T$52.9T
Goodwill and intangible assets$0.00$0.00
Long-term investments$0.00$0.00
Total non-current assets$51.5T$57T
Total assets$80.8T$149.3T
Accounts payable$17.3T$9.51T
Short-term debt$20.9T$9.38T
Deferred revenue$0.00$0.00
Total current liabilities$56.8T$32.4T
Long-term debt$37.8T$56.8T
Deferred revenue, non-current$0.00$0.00
Total non-current liabilities$40.6T$60.4T
Capital lease obligations$45.6T$50.9T
Total liabilities$97.3T$92.8T
Common stock$0.00$0.00
Retained earnings-$-541.5T-$-395.62T
Accumulated other comprehensive income (loss)$0.00$21B
Total equity-$-16.52T$56.4T
Total investments$0.00$40.7T
Total debt$58.7T$66.2T
Net debt$31T$18.9T
Cash flow statement
FYFY
Net income-$-145.89T-$-117.91T
Depreciation and amortization$2.5T$2.11T
Stock-based compensation$3.32T$4.31T
Change in working capital$9.12T$910B
Accounts receivable$360B$106B
Inventory$0.00$0.00
Accounts payable$13.6T$9.28T
Net cash provided by operating activities-$-123.71T-$-103.61T
Investments in property, plant and equipment-$-306B-$-879B
Acquisitions, net$0.00$0.00
Net cash used for investing activities$39.8T$30.2T
Common stock issued$67.5T$78.1T
Common stock repurchased$0.00$0.00
Dividends paid$0.00$0.00
Net cash used for financing activities$64.4T$78.1T
Net change in cash-$-19.57T$4.7T
Cash at end of period$30.6T$50.1T
Operating cash flow-$-123.71T-$-103.61T
Capital expenditure-$-306B-$-879B
Free cash flow-$-124.02T-$-104.49T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Parabilis Medicines, Inc.

        Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

        CEO
        Mathai Mammen
        Employees
        145
        Beta
        0.00

        Explore

        Frequently asked questions

        What is the intrinsic value of Parabilis Medicines, Inc. (PBLS)?

        Parabilis Medicines, Inc. (PBLS) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PBLS undervalued?

        PBLS trades at a price of $41.73 (Sep 19, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.